By Fineline Cube 
Daiichi Sankyo Co., Ltd. (TYO: 4568) and AstraZeneca plc (NYSE: AZN) announced the commercial launch of Datroway (datopotamab deruxtecan) in China, with initial shipments now being distributed to hospitals and pharmacies nationwide.
Product Profile & Clinical Indication
| Attribute | Detail |
|---|---|
| Drug Class | TROP2-targeting antibody drug conjugate (ADC) |
| Technology Platform | Daiichi Sankyo’s proprietary DXd ADC technology |
| Pipeline Status | One of six DXd ADCs in Daiichi Sankyo’s oncology pipeline; among AstraZeneca’s most advanced ADC programs |
| Approval Date (China) | August 2025 |
| Indication | Unresectable or metastatic HR-positive, HER2-negative breast cancer (IHC 0, IHC 1+, or IHC 2+/ISH-) in patients who have received prior endocrine therapy and at least one line of chemotherapy in the advanced setting |
| Pivotal Trial | Global Phase III TROPION-Breast01 study |
Strategic Significance
The Chinese launch represents a significant milestone in the companies’ global collaboration, addressing a substantial unmet need in China’s breast cancer landscape. With approximately 420,000 new breast cancer cases diagnosed annually in China—70% of which are HR-positive—the market opportunity for targeted therapies remains considerable.
Datroway leverages Daiichi Sankyo’s industry-leading DXd ADC platform, which enables high drug-to-antibody ratios and a membrane-permeable payload designed to enhance anti-tumor activity while maintaining manageable safety profiles.
Commercial Outlook
As part of their 50:50 joint development and commercialization agreement outside Japan, both companies will share promotional responsibilities in China. The launch follows successful regulatory approvals in the U.S., EU, and Japan, establishing Datroway as a cornerstone asset in the partners’ expanding oncology portfolios.
Forward-Looking Statements
This brief contains forward-looking statements regarding commercial launches, market opportunities, and development plans. Actual outcomes may differ based on market adoption, competitive dynamics, and regulatory developments.-Fineline Info & Tech